Core Viewpoint - Gyre Therapeutics reported financial results for Q2 2025, highlighting a net income of $1.6 million and reaffirming full-year revenue guidance of $118-128 million, driven by the expansion of its commercial portfolio and ongoing clinical trials [1][2][22]. Financial Performance - For the three months ended June 30, 2025, revenues were $26.8 million, an increase from $25.2 million in the same period of 2024, primarily due to the launch of Etorel and increased sales of Contiva [18][19]. - For the six months ended June 30, 2025, revenues totaled $48.8 million, down from $52.4 million in 2024, mainly due to a decline in ETUARY® sales [19][25]. - Net income for Q2 2025 was $1.6 million, compared to $4.5 million in Q2 2024, reflecting increased operating expenses [20][21]. Product and Pipeline Updates - The pivotal Phase 3 trial of Hydronidone for CHB-associated liver fibrosis showed statistically significant fibrosis regression after 52 weeks, with an NDA filing expected in Q3 2025 [4][15]. - Gyre launched Etorel in June 2025, generating $1.6 million in sales in its first partial quarter [5][6]. - The company plans to initiate a Phase 2 trial for Hydronidone in MASH-associated liver fibrosis in the second half of 2025 [4][15]. Leadership Changes - Dr. Han Ying transitioned from CEO to Senior Vice President, Science, while Ping Zhang was appointed as interim CEO [3][4][16]. Cash Position - As of June 30, 2025, Gyre held $75.9 million in cash and cash equivalents, reflecting an increase due to proceeds from a public offering [17][33]. Full Year Guidance - Gyre expects full-year 2025 revenues to be between $118 million and $128 million, representing growth of 11.3% to 20.8% over 2024, driven by new product launches [22][26].